Ukwahlula
I-Viekira Pak iyinxalenye yokusetyenziswa kweziyobisi ezisetyenziselwa ukunyanga ukusuleleka kwe- hepatitis C (HCV) . Ipakethi ibandakanya inqanaba elilodwa elichanekileyo lwe-Technivie ye-drug (ombitasvir + paritaprevir + ritonavir) ehlanganiswe kunye nedasabuvir.
Izixhobo zamachiza i-ombitasvir, i-paritaprevir kunye ne-dasabuvir ziyi-anti-virus (DAAs) ezichaphazelayo ukuphazamiseka kwentsholongwane.
I- ritonavir yeziyobisi, esetyenziswe rhoqo kwi- HIV yonyango , ifakiwe ukunyusa amayeza e-paritaprevir.
I-Viekira Pak idla ngokuphindaphindiweyo, kodwa kungekho rhoqo, ilawulwa ngokubambisana ne ribavirin kwaye ayifuni ukuba ithathwe nge- intergyon ye-pegylated (i-peg-interferon).
I-Viekira Pak yavunywa ngo-Disemba 19, 2014 yi-US Food and Drug Administration (FDA) ukuba isebenzise kubantu abadala kweminyaka engama-18 okanye ngaphezulu kunye ne-HCV ye-genotype 1 isifo, kuquka abo abane- cirrhosis ehlawulwe (apho isibindi sisasebenza) kunye nokufakelwa kwesibindi. Kwizigulane ezine-cirrhosis eziphuculweyo, i-Viekira Pak ayikhuthazwa.
I-Viekira Pak ibikwa ukuba inezinga lokunyanga lama-95% okanye ngaphezulu, nge-2% kuphela yezigulane eziphelisa unyango ngenxa yokunyamezela. Kufanelekileyo ukusetyenziswa kwizigulane ezine- HIV / HCV ukusulela usulelo .
Isistim
Amacwecwe amabini amacwecwe e-ombitasvir + paritaprevir + ritonavir (25mg / 150mg / 100mg) athatha enye imihla ngemihla ngokutya, kunye neetafile enye ye-dasabuvir ithathwa kabini imihla ngemihla ngokuhlwa nangokuhlwa ngokutya.
Amacwecwe afika ngokulula ngokulandelelanisa kwimihla ngemihla, kunye nemiyalelo ye-dosing efakwe kwibhokisi nganye. Ithebhulethi eyenziwe ngokubambisana i-pink, i-film-coated and embossed "AV1", ngelixa ithebhulethi ye-dasabuvir ibinki, i-film-coated and embossed "AV2".
Ukucetyiswa kweengcebiso
I-Viekira Pak imiselwe kwiikhosi ze-12 ukuya kwi-24 zeeveki ezingama-24, njengoko zilandelayo ziphakamiso:
- I-Genotype 1a ngaphandle kwe-cirrhosis: i-Viekira Pak ene-ribavirin iiveki ezili-12
- I-Genotype 1a nge-cirrhosis: I-Viekira Pak ene-ribavirin iiveki ezingama-24
- I-Genotype 1b ngaphandle kwe-cirrhosis: I-Viekira Pak yedwa kwiiveki ezili-12
- I-Genotype 1b ngaphandle kwe-cirrhosis: I-Viekira Pak ene-ribavirin iiveki ezingama-24
Izigulana zokufakelwa kwesibindi, i-Viekira Pak ingathathwa kunye ne-ribavirin kwiiveki ezingama-24 kuphela xa umsebenzi we-hepatic (isibindi) uqhelekileyo kwaye i-fibrosis (inqabile) encinci.
Iziphumo eziPhakathi
Iziphumo eziqhelekileyo ezimalunga nokusetyenziswa kwe-Viekira Pak (ezenzeka kwi-10% yezigulane) zi:
- Ukukhathala
- I sizathu
- Isikhumba esikhulayo
- Ukuguquka kwesibatho
- Ukungabikho
- Ukuthathaka nokukhathala
Ukusebenzisana kweziyobisi
Oku kulandelayo kufuneka kugwenywe xa usebenzisa i-Viekira Pak:
- I-Anticonvulsants: i-carbamazepine, i-phenytoin, i-phenobarbital
- I-Antihyperlipidemics (isetyenziswe ukunciphisa amanqanaba e-lipid egazini): gemfibrozil
- Iyeza-anti-arrhythmia: i-pimozide
- Iyeza zokunciphisa i-Cholesterol: i-lovastatin, i-simvastatin
- I-Erectile i-dysfunction medication: Viagra (sildenafil)
- I-Ergot eneeyeza (ezisetyenziselwa ukuphatha iintloko kunye nemigraines): i-ergotamine, i-dihydroergotamine, i-ergonovine, i-methylergonovine
- I-Ethinyl estradiol (uhlobo olwenziwa ngumntu lwe-estrogen)
- Iyeza-HIV : Sustiva (efavirenz) , Atripla (efavirenz + tenofovir + emtricitabine)
- I-Hypotension imithi: alfuzosin
- I-Rifampin-based based anti-tuberculosis amayeza: Mycobutin, Rifater, Rifamate, Rimactane, Rifadin, Priftin
- I-Sedatives: i-triazolam, imidazolam yomlomo
Ukungqinelana nokuqwalasela
Kwizigulane ezinokukhubazeka okwexeshana, i-Viekira Pak ayikhuthazwa. I-Viekira Pak inqatshelwe ukusetyenziswa kwezigulane ezinobungozi obunzima be-hepatic.
I-Viekira Pak iphinde iqhathaniswe nokusetyenziswa kwisigulane kunye ne-hypitometer eyaziwayo kwi-ritonavir (kubandakanywa noStevens-Johnson Syndrome, isifo esisongela ubomi, ukusabela komzimba wonke).
I-Viekira Pak inqatshelwe ukusetyenziswa kwabasetyhini abakhulelweyo xa besetyenziswe ne ribavirin.
Kunconywa ukuba bonke abafazi abaneminyaka engama-50 ubudala bahlolwe rhoqo ngenyanga ngokukhulelwa ngexesha loqeqesho. Kukwacetyiswa ukuba isigulane kunye nomlingani wakhe wesilisa banikezelwe ubuncinane iindlela ezimbini ezingekho-hormonal zokukhulelwa kwezilwanyana, kwaye zisetyenziswe ngexesha loqeqesho kunye neenyanga ezintandathu emva koko.
Umthombo:
US Administration and Drug Administration (FDA). "I-FDA ivumela i-Viekira Pak ukuphatha i-hepatitis C." Silver Spring, eMaryn; ukukhutshwa kwenkcazelo ekhutshwe ngoDisemba 19, 2014.